Pure Global

Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) - Trial NCT04826562

Access comprehensive clinical trial information for NCT04826562 through Pure Global AI's free database. This Phase 4 trial is sponsored by Saint Michael's Medical Center and is currently Not yet recruiting. The study focuses on Human Immunodeficiency Virus. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT04826562
Phase 4
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT04826562
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)

Study Focus

Dolutegravir/Lamivudine

Interventional

drug

Sponsor & Location

Saint Michael's Medical Center

Newark, United States of America

Timeline & Enrollment

Phase 4

Apr 01, 2021

Jun 01, 2023

40 participants

Primary Outcome

Virologic Failure

Summary

An open-label, pilot study of switching patients to Dovato who are currently taking Bitarvy
 who are virological suppressed (HIV-1 50 copies/mL

ICD-10 Classifications

Human immunodeficiency virus [HIV] disease
Unspecified human immunodeficiency virus [HIV] disease
Human immunodeficiency virus [HIV] disease resulting in other conditions
Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases
Asymptomatic human immunodeficiency virus [HIV] infection status

Data Source

ClinicalTrials.gov

NCT04826562

Non-Device Trial